Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Roche

Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details

Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic malignancies and solid tumors.

Benzinga

Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket

Shares of Poseida Therapeutics, Inc. (NASDAQ:PSTX) rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion deal.

Benzinga

Blood test could ‘reliably rule out’ Alzheimer’s, trial finds

There are hopes it will offer reassurance to patients with cognitive decline and help them avoid unnecessary further testing, researchers said.

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The Conversation

If You Hate Getting Pap Smears, Here’s Some Extremely Good News

The first self-administered tests for collecting vaginal samples are on the way to health care facilities, making Pap smears more accessible and tolerable.

Inverse

Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss

Roche is working on bringing its weight-loss medications to patients "faster than anticipated,” making it yet another contender in the weight-loss drug market.

Fortune

The Best European Stocks to Buy

European stocks are cheaper than their U.S. counterparts, and there are plenty of high-quality companies to choose from. Here's how you can find them.

Kiplinger

Read news from The Economist, FT, and more,
with one subscription

1st-of-its-kind Parkinson's treatment may slow aggressive disease, trial hints

A new antibody drug for Parkinson's disease appears to slow the progression of its movement-related symptoms, at least in some patients.

LiveScience

Revolutionary Antibiotic Breakthrough: Tackling Deadly Drug-Resistant Bacteria!

Researchers make strides in the battle against antibiotic resistance with a potential new class of drugs to combat drug-resistant bacteria, like CRAB.

Top News

Miniature organs on chips could revolutionize health-care research

To understand how bodies work, medical researchers and scientists have created mini models of organs, called organoids. This field of scientific research has had profound impacts on biological discovery and pharmaceutical development.

The Conversation

Patients in England will be first to access seven-minute cancer treatment jab

NHS is first health system to offer injection to hundreds of patients which will cut treatment times by up to three quarters

The Guardian - UK

Scottish firm working towards ‘transformative’ early blood test for Alzheimer’s

Scottish Brain Sciences is collaborating with Roche Diagnostics on the project.

The Independent UK

Pascal Soriot of AstraZeneca: ‘The climate crisis is a health crisis’

The man who led the drive to create a not-for-profit Covid vaccine is now focusing on the deaths caused by global heating and pollution

The Guardian - UK

Roche and ZS partner to set up dedicated centre in Chennai

Roche, a biopharmaceutical company and ZS a global management consulting and technology firm, on Friday announced the inauguration of a Business Operations Center for Advanced Analytics and Business Insights in Chennai.

The Hindu

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation

'The dirty disease' – both smokers and non-smokers get lung cancer. They face stigma on top of illness

Earlier this year, federal health minister Mark Butler announced a new national Lung Cancer Screening Program. The first of its kind for lung cancer, the screening program will open initially to current and former smokers aged 50 to 70 years by July 2025. It aims to save lives by detecting…

The Conversation

Billions is spent on cancer research globally – but is it money well spent?

In 2020, 19 million people around the world received a cancer diagnosis. By 2040, that number is expected to reach 28 million. Poorer countries will be especially hard hit, with an increasing number of cases and more deaths, compared with richer countries.

Cycling News

Tiffany Cromwell, Tasman Nankervis win Australia’s Nannup Gravel World Series race

Mark Chong second ahead of Nicolas Roche in men's category, Cassia Boglio and Courtney Sherwell complete women’s podium

StockNews.com

4 Stocks Under $30 to Buy Right Now

While a recession in 2023 looks inevitable amid lingering macro headwinds, experts believe it to be mild. Moreover, amid high hopes for a Santa Claus rally, quality stocks Stellantis (STLA), Albertsons Companies (ACI), Poseida Therapeutics (PSTX), and Civeo (CVEO) could be ideal buys under $30 now. Keep reading….

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Vet's lawsuit blaming antimalarial drug for psychosis tossed

A lawsuit against the maker of an anti-malarial drug blamed for causing psychotic and neurological damage in U.S. servicemembers has been thrown out

The Guardian - UK

Disappointment after potential Alzheimer’s drug fails Roche trial

Swiss pharmaceutical firm carried out two identical phase 3 trials of gantenerumab, with about 1,000 volunteers in each

Wales Online

Blow for people with Alzheimer's as 'promising' new Roche gantenerumab jab fails

The drug had held promise in earlier trials

The Independent UK

Alzheimer’s jab failed to meet goal on reducing memory decline, company says

Previous data had shown that gantenerumab reduced levels of brain amyloid plaque.

Tribune News Service

Regeneron, Bayer offer more promising data for aging eye drug

Bayer AG and Regeneron Pharmaceuticals Inc.’s blockbuster eye drug reached another clinical milestone by showing sustained efficacy in trials that could help the companies push back against a competing product from Roche Holding AG.

The Conversation

New Alzheimer's drug slows cognitive decline – and may be available as early as next year

Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.

Benzinga

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

Eli Lilly And Co (NYSE:LLY) - Market cap: $295 billion.

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.